A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis
Status:
Completed
Trial end date:
2020-11-26
Target enrollment:
Participant gender:
Summary
This multicenter study is being conducted to provide additional PF-06826647 safety and
tolerability data, and to further explore the clinical efficacy of PF-06826647 in the
treatment of moderate to severe plaque psoriasis. Additionally, the study is intended to
enable selection of oral dose and dosing regimen for the future clinical development of
PF-06826647.